Heron Therapeutics Stock News

So far Monday, June 29, NASDAQ is up 3.38% and the S&P is up 2.09%. Let’s take a look at

Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.

Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and

Its non-opioid painkiller gets a rejection over non-clinical issues.

Heron Therapeutics said on Monday the U.S. Food and Drug Administration has once again declined to approve its non-opioid painkiller for post-operative pain and sought more data, sending its shares do

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan

Heron Therapeutics Inc (NASDAQ:HRTX) was the target of some unusual options trading activity on Monday. Stock traders purchased 6,991 call options on the company. This represents an increase of approx

So far Sunday, June 28, NASDAQ is down -9.25% and the S&P is down -6.11%. Here are this morning’s most

So far Saturday, June 27, NASDAQ is down -9.25% and the S&P is down -6.11%. Here are this morning’s most

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) *

Alliancebernstein L.P. grew its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 107.5% during the first quarter, Holdings Channel.com reports. The firm owned 260,630 shares of the biotechnology co

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25) Brainstorm Cell...

Baird Financial Group Inc. raised its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 22.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exch

In this article you are going to find out whether hedge funds think Heron Therapeutics Inc (NASDAQ:HRTX) is a good investment right now. We like to check what the smart money thinks first before doing